Bouscarel B, Cortinovis C, Carpene C, Murat J C, Paris H
Eur J Pharmacol. 1985 Jan 2;107(2):223-31. doi: 10.1016/0014-2999(85)90062-7.
In the present work, [3H]clonidine was used to characterize alpha 2-adrenoceptors on the human adenocarcinoma cell line HT 29. The effects of alpha 2-adrenergic stimulation on cellular cyclic AMP levels were also investigated. The binding of [3H]clonidine on HT 29 cell membrane preparations was rapid and reversible. Scatchard analysis of the saturation curves indicated the existence of a single class of non-interacting sites with a KD of 1.29 +/- 0.07 nM and a Bmax of 114 +/- 7 fmol/mg of cell membrane protein. The binding sites for [3H]clonidine showed the required specificity for alpha 2-adrenoceptors. The potencies of alpha-adrenergic compounds to displace [3H]clonidine binding ranked as follows: yohimbine greater than phentolamine much greater than prazosin for antagonists and clonidine greater than epinephrine greater than norepinephrine greater than phenylephrine much greater than amidephrine for agonists. When tested on intact cells, epinephrine, norepinephrine and clonidine were found to counteract, in a dose-dependent manner, the increase of cyclic AMP triggered by vasoactive intestinal peptide (VIP). Such inhibitory effects were abolished by the addition of yohimbine but not of prazosin. The physiological amines were the most efficient agonists: both epinephrine and norepinephrine inhibited VIP-induced cyclic AMP accumulation by 50-55% with KD values of 50 nM and 300 nM respectively. Clonidine was a partial agonist only, provoking a weak (25-30%) inhibition of VIP-induced cyclic AMP accumulation even at high concentrations. These results indicate that, like normal colocytes, human colon adenocarcinoma cells HT 29 possess alpha 2-adrenoceptors, the stimulation of which is associated with an inhibition of cyclic AMP production.(ABSTRACT TRUNCATED AT 250 WORDS)
在本研究中,使用[3H]可乐定对人结肠腺癌细胞系HT 29上的α2 - 肾上腺素能受体进行表征。还研究了α2 - 肾上腺素能刺激对细胞环磷酸腺苷(cAMP)水平的影响。[3H]可乐定与HT 29细胞膜制剂的结合迅速且可逆。对饱和曲线的Scatchard分析表明存在一类单一的非相互作用位点,解离常数(KD)为1.29±0.07 nM,最大结合容量(Bmax)为114±7 fmol/mg细胞膜蛋白。[3H]可乐定的结合位点对α2 - 肾上腺素能受体具有所需的特异性。α - 肾上腺素能化合物取代[3H]可乐定结合的效力排序如下:对于拮抗剂,育亨宾大于酚妥拉明远大于哌唑嗪;对于激动剂,可乐定大于肾上腺素大于去甲肾上腺素大于苯肾上腺素远大于间羟胺。在完整细胞上进行测试时,发现肾上腺素、去甲肾上腺素和可乐定以剂量依赖性方式抵消血管活性肠肽(VIP)触发的环磷酸腺苷增加。加入育亨宾可消除这种抑制作用,但加入哌唑嗪则不能。生理性胺类是最有效的激动剂:肾上腺素和去甲肾上腺素分别以50 nM和300 nM的KD值抑制VIP诱导的环磷酸腺苷积累50 - 55%。可乐定只是一种部分激动剂,即使在高浓度下也只能对VIP诱导的环磷酸腺苷积累产生微弱(25 - 30%)的抑制作用。这些结果表明,与正常结肠细胞一样,人结肠腺癌细胞HT 29具有α2 - 肾上腺素能受体,其刺激与环磷酸腺苷产生的抑制有关。(摘要截短于250字)